Bispecific antibodies (BsAbs) and CAR-T cells are two promising immunotherapies for diffuse large B-cell lymphoma (DLBCL). CAR-T therapy, particularly CD19-directed CAR-19, has shown significant efficacy in relapsed/refractory DLBCL, with long-term disease-free survival rates of 30–40%. However, its use is limited by logistical challenges, high costs, and severe toxicities. BsAbs, such as glofitamab and epcoritamab, are easier to administer, have fewer side effects, and can be used in community settings. While they show promise in DLBCL, there is no convincing evidence of cure with BsAb monotherapy. BsAbs are being investigated in combination with CAR-T and as frontline therapy. Despite their advantages, BsAbs may not replace CAR-T, but could enhance its effectiveness or serve as an alternative. The future of DLBCL treatment will likely involve a combination of these therapies, with ongoing research to optimize both approaches. The role of BsAbs in DLBCL is evolving, and further studies are needed to determine their place in the treatment landscape. Both therapies have their own challenges, including cost, accessibility, and toxicity, which must be addressed to improve patient outcomes.Bispecific antibodies (BsAbs) and CAR-T cells are two promising immunotherapies for diffuse large B-cell lymphoma (DLBCL). CAR-T therapy, particularly CD19-directed CAR-19, has shown significant efficacy in relapsed/refractory DLBCL, with long-term disease-free survival rates of 30–40%. However, its use is limited by logistical challenges, high costs, and severe toxicities. BsAbs, such as glofitamab and epcoritamab, are easier to administer, have fewer side effects, and can be used in community settings. While they show promise in DLBCL, there is no convincing evidence of cure with BsAb monotherapy. BsAbs are being investigated in combination with CAR-T and as frontline therapy. Despite their advantages, BsAbs may not replace CAR-T, but could enhance its effectiveness or serve as an alternative. The future of DLBCL treatment will likely involve a combination of these therapies, with ongoing research to optimize both approaches. The role of BsAbs in DLBCL is evolving, and further studies are needed to determine their place in the treatment landscape. Both therapies have their own challenges, including cost, accessibility, and toxicity, which must be addressed to improve patient outcomes.